Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$951M |
| 2 |
Advanced Micro Devices
AMD
|
+$589M |
| 3 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$418M |
| 4 |
Lam Research
LRCX
|
+$412M |
| 5 |
Microsoft
MSFT
|
+$207M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$1.24B |
| 2 |
Apple
AAPL
|
+$585M |
| 3 |
STMP
Stamps.com, Inc.
STMP
|
+$111M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$87.8M |
| 5 |
TSMC
TSM
|
+$70.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.05% |
| 2 | Financials | 11.79% |
| 3 | Healthcare | 10.9% |
| 4 | Consumer Discretionary | 10.36% |
| 5 | Communication Services | 8.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Fortinet
FTNT
$117B
| $554K | ﹤0.01% |
9,480
+255
| +3% | +$14.8K |
|
627
Gilead Sciences
GILD
$162B
| $553K | ﹤0.01% |
7,912
-1,091
| -12% | -$76.6K |
|
628
First Trust Nasdaq-100 Select Equal Weight ETF
QQEW
$1.79B
| $553K | ﹤0.01% |
4,973
+3
| +0.1% | +$343 |
|
629
iShares Russell 2000 Value ETF
IWN
$14.5B
| $544K | ﹤0.01% |
3,394
+1,141
| +51% | +$183K |
|
630
STMicroelectronics
STM
$47.5B
| $541K | ﹤0.01% |
12,398
+29
| +0.2% | +$1.22K |
|
631
iQIYI
IQ
$1.24B
| $539K | ﹤0.01% |
67,088
+2,978
| +5% | +$30.9K |
|
632
Northrop Grumman
NOC
$80.7B
| $537K | ﹤0.01% |
1,491
+399
| +37% | +$144K |
|
|
ATVI
633
DELISTED
Activision Blizzard
ATVI
| $534K | ﹤0.01% |
6,894
+363
| +6% | +$30.3K |
|
634
Emerson Electric
EMR
$87.5B
| $533K | ﹤0.01% |
5,657
+1,378
| +32% | +$137K |
|
635
Fidelity MSCI Consumer Discretionary Index ETF
FDIS
$1.71B
| $533K | ﹤0.01% |
6,644
+1,642
| +33% | +$135K |
|
|
EGRX
636
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $533K | ﹤0.01% |
9,557
| – | – |
|
637
Prudential Financial
PRU
$41.9B
| $531K | ﹤0.01% |
5,047
+1,489
| +42% | +$153K |
|
638
Brookfield
BN
$108B
| $527K | ﹤0.01% |
18,290
-200
| -1% | -$5.84K |
|
639
Vanguard Tax-Exempt Bond Index Fund
VTEB
$45.2B
| $526K | ﹤0.01% |
9,608
-68
| -0.7% | -$3.76K |
|
640
VeriSign
VRSN
$26.4B
| $518K | ﹤0.01% |
2,526
-12
| -0.5% | -$2.63K |
|
641
Illinois Tool Works
ITW
$84.8B
| $515K | ﹤0.01% |
2,492
+744
| +43% | +$168K |
|
642
iShares MSCI Germany ETF
EWG
$1.61B
| $509K | ﹤0.01% |
15,465
-99
| -0.6% | -$3.42K |
|
|
ACC
643
DELISTED
American Campus Communities, Inc.
ACC
| $509K | ﹤0.01% |
10,506
+24
| +0.2% | +$1.19K |
|
644
KLA
KLAC
$252B
| $506K | ﹤0.01% |
15,120
+1,470
| +11% | +$49.1K |
|
|
IMGN
645
DELISTED
Immunogen Inc
IMGN
| $481K | ﹤0.01% |
84,798
-271
| -0.3% | -$1.57K |
|
646
Dimensional US Core Equity 2 ETF
DFAC
$49.1B
| $475K | ﹤0.01% |
17,884
| – | – |
|
647
Exelon
EXC
$46.7B
| $472K | ﹤0.01% |
13,679
+701
| +5% | +$24K |
|
|
NSA
648
DELISTED
National Storage Affiliates Trust
NSA
| $469K | ﹤0.01% |
8,878
| – | – |
|
649
Marathon Petroleum
MPC
$84B
| $462K | ﹤0.01% |
7,479
-1,012
| -12% | -$58.2K |
|
650
DuPont de Nemours
DD
$19.5B
| $460K | ﹤0.01% |
5,386
+55
| +1% | +$5.1K |
|
Similar funds
Ken Fisher's Q3 2021 Portfolio in Review
As of Q3 2021, Ken Fisher held 1,103 positions worth $161B, up 1.1% from $159B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Fisher's Q3 2021 filing shows 93 new, 444 increased, 375 reduced and 75 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 267,976 shares worth $37.2M. The largest sale was Visa, an estimated $1.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
- Ken Fisher's largest Q3 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 267,976 shares worth $37.2M.
- Ken Fisher added most to Meta Platforms (Facebook) in Q3 2021, an estimated $951M increase.
- Ken Fisher's biggest Q3 2021 reduction was Visa, cutting an estimated $1.24B.
- Ken Fisher fully exited Stamps.com, Inc. in Q3 2021, selling an estimated $111M.
- Ken Fisher's ten largest holdings make up 31% of its $161B portfolio in Q3 2021.
- Ken Fisher opened 93 new positions and closed 75 in Q3 2021.
- Ken Fisher's portfolio value rose 1.1% quarter-over-quarter to $161B.
Based on Fisher Asset Management's 13F filing for Q3 2021, filed 26 Oct 2021.